LHDXQ — Lucira Health Share Price
0.000.00%
Last trade - 00:00FinancialsHighly SpeculativeMicro Cap
- $0.00m
- -$10.36m
- $93.06m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | 0 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -133.01% | ||
| Return on Equity | -112.43% | ||
| Operating Margin | -66.88% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 0.27 | 93.06 | 185.67 | 120 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lucira Health, Inc. is a United States-based company. The Company has no business operations and is in liquidation.
Directors
- Erik Engelson PRE (61)
- Daniel George CFO (51)
- Hansgregory Hartmann COO (63)
- Ghazi Kashmolah EVP
- Kelly Lewis Brezoczky EVP (57)
- Debkishore Mitra CTO (34)
- Tamanna Prashar VOP (40)
- Sandra Gardiner IND (55)
- David Lamond IND (46)
- Erica Rogers IND (58)
- Lior Susan IND (37)
- Steve Tablak IND (61)
- Tuff Yen IND (58)
- Last Annual
- December 31st, 2021
- Last Interim
- September 30th, 2022
- Incorporated
- February 20th, 2013
- Public Since
- February 5th, 2021
- No. of Shareholders
- 60
- No. of Employees
- 221
- Sector
- Holding Companies
- Industry
- Financials
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 40,598,954
- Address
- 1315 63Rd Street, EMERYVILLE, 94608
- Web
- https://www.lucirahealth.com/
- Phone
- +1 8145741546
- Contact
- Greg Chodaczek
- Auditors
- BDO USA, LLP
Upcoming Events for LHDXQ
Q4 2022 Lucira Health Inc Earnings Release
Q3 2023 Lucira Health Inc Earnings Release
Similar to LHDXQ
12 Retech
Pink Sheets on Nasdaq
1399 Internet Technology Application
Pink Sheets on Nasdaq
3D Pioneer Systems
Pink Sheets on Nasdaq
9 Meters Biopharma
Pink Sheets on Nasdaq
A1
Pink Sheets on Nasdaq
FAQ
What is the Lucira Health share price?
As of Today at 01:13 UTC, shares in Lucira Health are trading at $0.00. This share price information is delayed by 15 minutes.
How has the Lucira Health share price performed this year?
Shares in Lucira Health last closed at $0.00 and the price had moved by -99.97% over the past 365 days. In terms of relative price strength the Lucira Health share price has underperformed the S&P500 Index by -99.97% over the past year.
What are the analyst and broker recommendations for Lucira Health?
The overall consensus recommendation for Lucira Health is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Lucira Health dividend yield?
Lucira Health does not currently pay a dividend.
Does Lucira Health pay a dividend?
Lucira Health does not currently pay a dividend.
When does Lucira Health next pay dividends?
Lucira Health does not currently pay a dividend.
How do I buy Lucira Health shares?
To buy shares in Lucira Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Lucira Health?
As of the previous close price of $0.00, shares in Lucira Health had a market capitalisation of $0.04m.
Where are Lucira Health shares listed?
Here are the trading details for Lucira Health:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: LHDXQ
What kind of share is Lucira Health?
Based on an overall assessment of its quality, value and momentum Lucira Health is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Lucira Health share price forecast for 2023?
The analyst consensus target price for shares in Lucira Health is $0.50. That is 49900% above the last closing price of $0.00.
Analysts covering Lucira Health currently have a consensus Earnings Per Share (EPS) forecast of -$0.23 for the next financial year.
Find out moreWhat is the trend in the Lucira Health share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lucira Health. Over the past six months, its share price has underperformed the S&P500 Index by -99.7%.
As of the last closing price of $0.00, shares in Lucira Health were trading -99.68% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Lucira Health PE Ratio?
The Lucira Health PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Lucira Health?
Lucira Health's management team is headed by:
- Erik Engelson - PRE
- Daniel George - CFO
- Hansgregory Hartmann - COO
- Ghazi Kashmolah - EVP
- Kelly Lewis Brezoczky - EVP
- Debkishore Mitra - CTO
- Tamanna Prashar - VOP
- Sandra Gardiner - IND
- David Lamond - IND
- Erica Rogers - IND
- Lior Susan - IND
- Steve Tablak - IND
- Tuff Yen - IND